Table S4: Sub-group Analyses for the Association between ADMA and Outcomes in the HEMO Study

Strata (N)	Cardiac Death		Sudden Cardiac Death		First Cardiovascular Event or Any-Cause Death		Any-Cause Death	
	HR (95% CI)	P[1]	HR (95% CI)	P[1]	HR (95% CI)	P[1]	HR (95% CI)	P[1]
Entire Sample Overall (1276)	1.83 (1.29-2.58)		1.79 (1.19-2.69)		1.50 (1.20-1.87)		1.44 (1.13-1.83)	
Age < 59 years (638)	2.84 (1.56-5.18)	0.1	3.14 (1.28-7.69)	0.1	1.39 (0.97-1.98)	0.6	1.51 (1.00-2.29)	0.8
Age ≥ 59 years (638)	1.45 (0.89-2.37)		1.21 (0.71-2.07)		1.59 (1.16-2.16)		1.40 (1.00-1.98)	
Male (552)	1.63 (0.90-2.95)	0.5	1.94 (1.00-3.77)	0.7	1.73 (1.21-2.48)	0.2	1.50 (1.03-2.18)	0.8
Female (724)	2.01 (1.38-2.93)		1.67 (1.07-2.60)		1.37 (1.08-1.73)		1.39 (0.99-1.95)	
Non-Black (474)	1.95 (1.18-3.22)	0.8	2.36 (1.16-4.81)	0.3	1.36 (0.88-2.09)	0.6	1.33 (0.96-1.82)	0.5
Black (801)	1.74 (1.05-2.87)		1.44 (0.87-2.37)		1.57 (1.22-2.02)		1.51 (1.12-2.03)	
Diabetes = No (699)	2.11 (1.14-3.89)	0.6	3.11 (1.49-6.51)	**0.03**	1.35 (1.00-1.82)	0.3	1.46 (1.02-2.08)	0.9
Diabetes = Yes (571)	1.67 (1.08-2.59)		1.28 (0.85-1.94)		1.67 (1.21-2.30)		1.42 (1.07-1.88)	
Cardiac Disease = No (271)	2.00 (0.67-5.95)	0.8	0.61 (0.05-6.90)	0.4	2.13 (1.26-3.61)	0.2	1.79 (1.00-3.20)	0.5
Cardiac Disease = Yes (1005)	1.75 (1.18-2.61)		1.83 (1.17-2.86)		1.39 (1.06-1.83)		1.37 (1.03-1.82)	
GI Disease = No (798)	1.70 (1.07-2.72)	0.6	1.58 (0.92-2.72)	0.6	1.69 (1.31-2.19)	0.2	1.55 (1.18-2.02)	0.4
GI Disease = Yes (478)	2.06 (1.10-3.87)		1.98 (1.04-3.79)		1.21 (0.82-1.79)		1.32 (0.91-1.91)	
BMI < 18 kg/m^2 (42)	7.61 (0.98-58.9)	0.2	5.44 (0.37-79.6)	0.4	5.20 (0.76-35.7)	0.2	3.13 (0.56-17.4)	0.4
BMI 18 to 25 kg/m^2 (621)	2.04 (1.24-3.37)		2.85 (1.40-5.78)		1.47 (1.15-1.89)		1.75 (1.33-2.30)	
BMI > 25 kg/m^2 (613)	1.57 (0.90-2.74)		1.12 (0.57-2.19)		1.43 (1.02-2.01)		1.14 (0.80-1.61)	
Albumin < 3.6 g/dL (566)	1.93 (1.18-3.18)	0.8	1.71 (0.87-3.37)	0.8	1.39 (1.08-1.77)	0.4	1.37 (0.99-1.91)	0.7
Albumin ≥ 3.6 g/dL (704)	1.74 (0.89-3.40)		1.98 (0.91-4.31)		1.61 (1.17-2.22)		1.52 (1.04-2.23)	
Standard Dose (641)	1.56 (0.99-2.46)	0.3	1.61 (0.86-3.02)	0.7	1.31 (0.95-1.82)	0.2	1.29 (0.93-1.80)	0.2
High Dose (635)	2.18 (1.39-3.43)		1.99 (1.08-3.66)		1.69 (1.31-2.19)		1.60 (1.24-2.07)	
Low-Flux (640)	1.41 (0.84-2.37)	0.04	1.18 (0.62-2.24)	**0.04**	1.51 (1.18-1.95)	0.9	1.43 (1.00-2.04)	0.9
High-Flux (636)	2.76 (1.97-3.86)		3.32 (1.75-6.30)		1.46 (1.04-2.05)		1.43 (1.03-1.98)	
RKF = No (842)	1.64 (1.12-2.40)	0.09	1.51 (0.96-2.39)	0.2	1.50 (1.16-1.93)	0.9	1.35 (1.01-1.81)	0.2
RKF = Yes (433)	2.45 (1.60-3.75)		2.79 (1.20-6.47)		1.51 (1.06-2.14)		1.67 (1.28-2.16)	

Abbreviation: HR, Hazard Ratio; CI, Confidence Interval; ADMA, Asymmetric Dimethylarginine; GI, Gastrointestinal; BMI, Body Mass Index; RKF, Residual Kidney Function

HR represents increase in risk per 2-fold increase in ADMA or SDMA concentrations. Modeled as natural log transformed variable/natural log of 2.

Model 4 adjusted for age, sex, race, Index of Coexisting Disease (ICED) severity score, cause of end-stage renal disease, body mass index (categorized as <18, 18 to 25 and >25 kg/m^2), systolic blood pressure (categorized as <130, 130-160 and >160 mm Hg), albumin, relative volume removed on dialysis and residual kidney function (urinary stdKt/V$_{UREA}$ calculated from urinary urea clearance).

[1] P-interactions between groups for the subgroup analyses.